Sarepta Therapeutics Stock Analysis (NASDAQ:SRPT)

Add to My Stocks
$43.95 $0.54 (1.24%) SRPT stock closing price Jul 24, 2017 (Closing)
Watch Robo Advisor Video of SRPT Stock Analysis
Sarepta Therapeutics
Updated on : Jul 21, 2017
previous close
SRPT 43.4 (0%)
S&P 500 2472.5 (0%)
Closing Price On: Jul 21, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2017-Q1
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
-13.1%
5 Quarter Net Profit
Net Margins
2017-Q1
%
LTM Margin
Debt/Equity Ratio
Debt:
13.7M
Debt/Equity Ratio:
 0.03
Compared to the industry
Cash Flow
Operating cash flow:
-$57.9M
Net Income:
$84.1M
PROS      CONS
Low Debt Burden
Recent Growth
Long Term Growth
Net Margins
Cash Flow
ROE
FCF Margin
Rating: ★★★★★★★★★★ (0/5)
Other Metrics
Return on Equity:
-37.6%
Free Cash Flow Margin:
-381.5%
Double Tap To Exit Full Screen
0:00
/

Sarepta Therapeutics Analysis Video

171 5 2

View Sarepta Therapeutics stock analysis video. This is our SRPT analyst opinion covering the buy and sell arguments for SRPT stock.

Sarepta Therapeutics Inc Stock Rating (1.2/5)

Our Sarepta Therapeutics stock opinion is based on fundamentals of the company. This Sarepta Therapeutics stock analysis is based on latest Q1 earnings for 2017. The stock price analysis takes into account a company's valuation metrics.

Should you buy SRPT stock?

  • With its debt/equity ratio of  0.03, Sarepta Therapeutics has a lower debt burden when compared to the Medical average.

Should you sell SRPT stock?

  • Sarepta Therapeutics sales shrank by -999% year-over-year in 2017 Q1.
  • Sales declined by -13.1% annually over the last 5 years.
  • Sarepta Therapeutics registered an average TTM Net loss of -567.1%.
  • A negative ROE of -37.6% indicates that the company is not able to generate profits with the money shareholders have invested.
  • Sarepta Therapeutics has a negative FCF (Free Cash Flow) margin of -381.5%.

Comments on this video and Sarepta Therapeutics stock